Trial Information

For the esophageal carcinoma in II~III stage, routine dosage of Paclitaxel and platinum
medicine chemotherapy concurrently radical radiotherapy is worthy to be studied. On this
base, we advanced approach the enlarged field radiotherapy and the intervention of Tarceva.
And we approach the therapeutic effect for this method theoretically, which may give a
further reasonable guidance for the clinical therapy.

Inclusion Criteria:

1. Subjects must be confirmed Esophageal Carcinoma pathologically

2. (EUS)I～IVa, without contraindication for radical radiotherapy

3. Subjects haven't been given neither radiotherapy nor chemotherapy before

8. Female subjects who have the ability of fertility should take contraception during
the whole course and also 3 months after last dosage.In 7 days before the inclusion,
urine pregnancy tests of subjects should be negative.

Exclusion Criteria:

1. Patients who have uncontrolled infection or severe medical disease

2. Patient who used to appear 4th stage swallowing obstruction or
perforation/symptomatic-perforation after radiotherapy

3. Patients who are/were given any other medicine tests currently/in last 4 weeks

4. Experienced hypersensitiveness with similar medicine or other kinds of bio-medicines

5. Women in status of pregnancy

6. Patients with main organ failure

7. Other kinds of abnormal, e.g: mental anomaly, drug abuse, alcohol abuse, and such so
on, with which will not fit for this study.

Start Date:

Completion Date:

Related Keywords:

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.